Logo image of ORIC

ORIC PHARMACEUTICALS INC (ORIC) Stock Fundamental Analysis

USA - NASDAQ:ORIC - US68622P1093 - Common Stock

12.35 USD
-0.2 (-1.59%)
Last: 11/7/2025, 8:06:19 PM
12.59 USD
+0.24 (+1.94%)
After Hours: 11/7/2025, 8:06:19 PM
Fundamental Rating

3

Overall ORIC gets a fundamental rating of 3 out of 10. We evaluated ORIC against 535 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ORIC as it has an excellent financial health rating, but there are worries on the profitability. ORIC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ORIC had negative earnings in the past year.
ORIC had a negative operating cash flow in the past year.
ORIC had negative earnings in each of the past 5 years.
ORIC had a negative operating cash flow in each of the past 5 years.
ORIC Yearly Net Income VS EBIT VS OCF VS FCFORIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of ORIC (-39.69%) is comparable to the rest of the industry.
ORIC has a Return On Equity of -42.50%. This is in the better half of the industry: ORIC outperforms 70.15% of its industry peers.
Industry RankSector Rank
ROA -39.69%
ROE -42.5%
ROIC N/A
ROA(3y)-40.88%
ROA(5y)-34.73%
ROE(3y)-45.86%
ROE(5y)-38.37%
ROIC(3y)N/A
ROIC(5y)N/A
ORIC Yearly ROA, ROE, ROICORIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ORIC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORIC Yearly Profit, Operating, Gross MarginsORIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ORIC has been increased compared to 1 year ago.
The number of shares outstanding for ORIC has been increased compared to 5 years ago.
ORIC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ORIC Yearly Shares OutstandingORIC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ORIC Yearly Total Debt VS Total AssetsORIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 28.46 indicates that ORIC is not in any danger for bankruptcy at the moment.
The Altman-Z score of ORIC (28.46) is better than 93.28% of its industry peers.
There is no outstanding debt for ORIC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 28.46
ROIC/WACCN/A
WACCN/A
ORIC Yearly LT Debt VS Equity VS FCFORIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 16.13 indicates that ORIC has no problem at all paying its short term obligations.
ORIC has a better Current ratio (16.13) than 91.23% of its industry peers.
ORIC has a Quick Ratio of 16.13. This indicates that ORIC is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 16.13, ORIC belongs to the best of the industry, outperforming 91.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.13
Quick Ratio 16.13
ORIC Yearly Current Assets VS Current LiabilitesORIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ORIC have decreased by -8.00% in the last year.
EPS 1Y (TTM)-8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ORIC will show a small growth in Earnings Per Share. The EPS will grow by 4.70% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.32%
EPS Next 2Y2.28%
EPS Next 3Y2.08%
EPS Next 5Y4.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORIC Yearly Revenue VS EstimatesORIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ORIC Yearly EPS VS EstimatesORIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ORIC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ORIC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORIC Price Earnings VS Forward Price EarningsORIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORIC Per share dataORIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.28%
EPS Next 3Y2.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ORIC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORIC PHARMACEUTICALS INC

NASDAQ:ORIC (11/7/2025, 8:06:19 PM)

After market: 12.59 +0.24 (+1.94%)

12.35

-0.2 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10
Inst Owners96.14%
Inst Owner Change-1.73%
Ins Owners1.43%
Ins Owner Change-2.57%
Market Cap1.20B
Revenue(TTM)N/A
Net Income(TTM)-137.68M
Analysts88.89
Price Target18.77 (51.98%)
Short Float %14.69%
Short Ratio10.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.71%
Min EPS beat(2)-4.01%
Max EPS beat(2)19.44%
EPS beat(4)2
Avg EPS beat(4)4.02%
Min EPS beat(4)-4.01%
Max EPS beat(4)19.44%
EPS beat(8)5
Avg EPS beat(8)4.21%
EPS beat(12)8
Avg EPS beat(12)3.73%
EPS beat(16)10
Avg EPS beat(16)4.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.66%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.66%
EPS NY rev (1m)0%
EPS NY rev (3m)7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.7
P/tB 3.7
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.74
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0
BVpS3.34
TBVpS3.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.69%
ROE -42.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.88%
ROA(5y)-34.73%
ROE(3y)-45.86%
ROE(5y)-38.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.51%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.13
Quick Ratio 16.13
Altman-Z 28.46
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)134.67%
Cap/Depr(5y)115.51%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.44%
EPS Next Y7.32%
EPS Next 2Y2.28%
EPS Next 3Y2.08%
EPS Next 5Y4.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.16%
EBIT Next 3Y-6.98%
EBIT Next 5YN/A
FCF growth 1Y-55.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.08%
OCF growth 3YN/A
OCF growth 5YN/A

ORIC PHARMACEUTICALS INC / ORIC FAQ

Can you provide the ChartMill fundamental rating for ORIC PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ORIC.


What is the valuation status for ORIC stock?

ChartMill assigns a valuation rating of 0 / 10 to ORIC PHARMACEUTICALS INC (ORIC). This can be considered as Overvalued.


How profitable is ORIC PHARMACEUTICALS INC (ORIC) stock?

ORIC PHARMACEUTICALS INC (ORIC) has a profitability rating of 1 / 10.


How financially healthy is ORIC PHARMACEUTICALS INC?

The financial health rating of ORIC PHARMACEUTICALS INC (ORIC) is 8 / 10.


What is the earnings growth outlook for ORIC PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ORIC PHARMACEUTICALS INC (ORIC) is expected to grow by 7.32% in the next year.